Chemoradiotherapy for extrahepatic bile duct cancer with gross residual disease after surgery

Hae Jin Park, Kyubo Kim, Eui Kyu Chie, Jin Young Jang, Sun Whe Kim, Sae Won Han, Do Youn Oh, Seock Ah Im, Tae You Kim, Yung Jue Bang, Sung W. Ha

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Background: The purpose of the present study was to analyze the outcome of chemoradiotherapy for extrahepatic bile duct (EHBD) cancer patients with gross residual disease after surgical resection. Patients and Methods: We retrospectively analyzed 30 patients with EHBD adenocarcinoma who underwent chemoradiotherapy after palliative resection (R2 resection). Postoperative radiotherapy was delivered to the tumor bed including residual tumor and regional lymph nodes (range=40-55.8 Gy). Most patients underwent chemoradiotherapy concurrently with 5-fluorouracil (5-FU) or gemcitabine. Results: The 2-year locoregional progression-free, distant metastasis-free and overall survival rates were 33.3%, 42.4% and 44.5%, respectively. High radiation dose ≥50 Gy had a marginally significant impact on superior locoregional progression-free survival compared to 40 Gy (p=0.081). One patient developed grade 3 late gastrointestinal toxicity. Conclusion: Adjuvant chemoradiotherapy for EHBD cancer patients with gross residual disease after surgery was well-tolerated. There could be a chance for durable locoregional control and even long-term survival in selected patients.

Original languageEnglish
Pages (from-to)6685-6690
Number of pages6
JournalAnticancer Research
Issue number11
StatePublished - 1 Nov 2014

Bibliographical note

Publisher Copyright:
© 2014, International Institute of Anticancer Research. All rights reserved.


  • Chemoradiotherapy
  • Extrahepatic bile duct cancer
  • Failure pattern
  • R2 resection


Dive into the research topics of 'Chemoradiotherapy for extrahepatic bile duct cancer with gross residual disease after surgery'. Together they form a unique fingerprint.

Cite this